Shares of Fennec Pharmaceuticals Inc. (FENC) touched a new 52-week high of $8.26 yesterday, driven by the company's optimized sales strategy for its lead product, Pedmark, and its successful expansion into additional markets.
Pedmark is the first and only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is also recommended for the Adolescent and Young Adult (AYA) population by the National Comprehensive Cancer Network as a preventative treatment option to reduce hearing loss associated with platinum-based chemotherapy in patients with localized, non-metastatic tumors.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com